Claritas (formerly Kalytera Therapeutics, Inc.) to Collaborate with Salzman Group and Other Companies to Accelerate Development of R-107 for Treatment of Vaccine-Resistant COVID-19, Influenza, and Other Viral Infections
Under the Collaboration Agreement, Salzman Group will make available to Claritas the full capabilities of Salzman Group, including its expertise in working with nitric oxide and nitric oxide releasing compounds.
- Under the Collaboration Agreement, Salzman Group will make available to Claritas the full capabilities of Salzman Group, including its expertise in working with nitric oxide and nitric oxide releasing compounds.
- Dr. Salzman received his undergraduate degree from Yale University and his medical degree from Harvard Medical School.
- Dr. Salzman has taken 12 of his pharmaceutical inventions from the bench into the clinic.
- Dr. Jagtap has over 50 patents co-invented with Dr. Salzman, and has co-developed over 8 small molecules with him over his career.